Results 1 to 10 of about 11,800 (145)
CDK4/6 inhibitors combined with fulvestrant for the treatment of HR+/HER2–advanced or metastatic breast cancer: a Bayesian network meta-analysis [PDF]
BMC CancerBackground This study aimed to assess the efficacy and safety of different CDK4/6 inhibitors combined with fulvestrant in treating HR+/HER2– advanced or metastatic breast cancer, using a Bayesian network meta-analysis.
Yanmin Deng +3 more
doaj +2 more sources
Fulvestrant: pharmacokinetics and pharmacology [PDF]
British Journal of Cancer, 2004 Fulvestrant is a new type of oestrogen receptor (ER) antagonist with no agonist activity and a novel pharmacological profile. Fulvestrant has been shown to significantly reduce cellular levels of the ER and progesterone receptor in both preclinical studies and in clinical trials of postmenopausal women with primary breast cancer. This paper reviews the
J F R Robertson, Robertson J F R
exaly +3 more sources
BRD4 PROTAC degrader enhances fulvestrant sensitivity in ER+ breast cancer via super-enhancer associated GREB1 [PDF]
Frontiers in OncologyBackgroundBreast cancer has the highest incidence and mortality among all cancers affecting women. Fulvestrant resistance remains a major clinical challenge that limits the efficacy of endocrine therapies.
Xiulei Zhang +6 more
doaj +2 more sources
A method to detect fulvestrant interference in estradiol in breast cancer patients
Endocrine Connections, 2023 Background: Fulvestrant resembles estradiol in its structure. Reports have been published concerning fulvestrant measured as estradiol by the immunoassays. This may induce falsely elevated estradiol results and wrongly impact medical decisions.
Margarida Brito +2 more
doaj +1 more source
Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo. [PDF]
PLoS ONE, 2013 Pure anti-estrogen fulvestrant has been shown to be a promising ER antagonist for locally advanced and metastatic breast cancer. Unfortunately, a significant proportion of patients developed resistance to this type of endocrine therapy but the molecular ...
Lijiang Zhang +5 more
doaj +1 more source
Медицинский совет, 2020 The review presents the results of studies of fulvestrant in metastatic breast cancer (MBC). Hormone therapy is an effective method of treating hormone-positive metastatic breast cancer even in the presence of visceral metastases in the absence of a ...
I. A. Koroleva, M. V. Kopp
doaj +1 more source
npj Breast Cancer, 2021 Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies are urgently needed.
Lillian M. Smyth +26 more
doaj +1 more source
Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer. [PDF]
PLoS ONE, 2014 Fulvestrant (ICI-182,780) has recently been shown to effectively suppress prostate cancer cell growth in vitro and in vivo. But it is unclear whether microRNAs play a role in regulating oncogene expression in fulvestrant-treated prostate cancer.
Yuet-Kin Leung +8 more
doaj +1 more source
Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase. [PDF]
PLoS ONE, 2013 Fulvestrant is a representative pure antiestrogen and a Selective Estrogen Receptor Down-regulator (SERD). In contrast to the Selective Estrogen Receptor Modulators (SERMs) such as 4-hydroxytamoxifen that bind to estrogen receptor α (ERα) as antagonists ...
Wei-Lan Yeh +5 more
doaj +1 more source
Breast Cancer Research, 2021 Background In MONARCH 2, abemaciclib plus fulvestrant significantly improved median progression-free survival (PFS, 16.4 vs 9.3 months, hazard ratio [HR] 0.553) and overall survival (OS, 46.7 vs 37.3 months; HR 0.757) compared with placebo plus ...
Patrick Neven +10 more
doaj +1 more source